Theriva Biologics (TOVX) Stock Statistics & Valuation Metrics

Theriva Biologics has a market cap or net worth of $4.37M. The enterprise value is -$4.30M.

Theriva Biologics has 9,059,232 shares outstanding. The number of shares has decreased by -2.65% in one year.

Theriva Biologics’s return on equity (ROE) is -1.35 and return on invested capital (ROIC) is -91.14%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Theriva Biologics had revenue of 0.00 and earned -25.65M in profits. Earnings per share was -19.03.

In the last 12 months, operating cash flow was -32.70M and capital expenditures -462.00K, giving a free cash flow of -33.16M billion.

Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Theriva Biologics upcoming earnings date is Aug 7, 2025, After Close (Confirmed).

Theriva Biologics as a current ratio of 2.15, with Debt / Equity ratio of 8.72%

In the past 12 months, Theriva Biologics has paid 0.00 in taxes.

Theriva Biologics EV to EBITDA ratio is 0.29, with an EV/FCF ratio of 0.45.

Theriva Biologics has $10.01M in cash and marketable securities with $2.85M in debt, giving a net cash position of -$7.16M billion.

Gross margin is 25.32%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Theriva Biologics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy